CompletedPhase 2NCT04658823
Efficacy and Safety of Tocotrienols in CADASIL
Studying Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hovid Berhad
- Principal Investigator
- Pr Hugues ChabriatHôpital Lariboisière APHP
- Intervention
- HOV-12020 (Palm tocotrienols complex)(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 45-75 years · All sexes
- Timeline
- 2020 – 2024
Study locations (1)
- Hôpital Lariboisière APHP, Paris, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04658823 on ClinicalTrials.govOther trials for Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT05755997CERebrolysin In CADASILEver Neuro Pharma GmbH
- RECRUITINGNCT06148051AusCADASIL: An Australian Cohort of CADASILPerminder Sachdev
- RECRUITINGNCT06938100Genotype, Clinical Features and Imaging of Neuroradiological Abnormalities in CADASILFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- RECRUITINGNANCT06935578RAre, But Not aLone: a Large Italian Network to Empower the Impervious diaGNostic Pathway of Rare cerEbrovascular Diseases (ALIGNED)Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- RECRUITINGNCT05072483Natural History Study of CADASILNational Heart, Lung, and Blood Institute (NHLBI)